Article Text
Therapeutics
Systematic review
Combination therapy with long-acting β-agonists plus inhaled corticosteroids is no more effective than LABA monotherapy for mortality outcomes and severe exacerbations in moderate to very severe COPD and is associated with serious adverse effects
Statistics from Altmetric.com
Footnotes
-
Competing interests PAF has received funds for undertaking multi-centre clinical trials, speaker fees, consulting fees, reimbursements for attending symposia and support for organising education from Altana Pharma, AstraZeneca, Bayer, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Nycomed and Pfizer.